vs
Equity Residential（EQR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Equity Residential的季度营收约是Revvity的1.0倍（$781.9M vs $772.1M），Equity Residential净利率更高（48.9% vs 12.7%，领先36.1%），Revvity同比增速更快（5.9% vs 2.0%），过去两年Revvity的营收复合增速更高（9.0% vs 3.4%）
Equity Residential是总部位于美国的公开上市房地产投资信托基金（REIT），核心业务聚焦公寓类不动产投资，在全美多地持有大量优质公寓资产，深耕租赁住房市场，拥有成熟的运营管理经验和突出的行业竞争优势。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EQR vs RVTY — 直观对比
营收规模更大
EQR
是对方的1.0倍
$772.1M
营收增速更快
RVTY
高出3.9%
2.0%
净利率更高
EQR
高出36.1%
12.7%
两年增速更快
RVTY
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $781.9M | $772.1M |
| 净利润 | $382.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 14.5% |
| 净利率 | 48.9% | 12.7% |
| 营收同比 | 2.0% | 5.9% |
| 净利润同比 | -8.8% | 3.9% |
| 每股收益（稀释后） | $1.01 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EQRRVTY
| Q4 25 | $781.9M | $772.1M | ||
| Q3 25 | $782.4M | $698.9M | ||
| Q2 25 | $768.8M | $720.3M | ||
| Q1 25 | $760.8M | $664.8M | ||
| Q4 24 | $766.8M | $729.4M | ||
| Q3 24 | $748.3M | $684.0M | ||
| Q2 24 | $734.2M | $691.7M | ||
| Q1 24 | $730.8M | $649.9M |
净利润EQRRVTY
| Q4 25 | $382.1M | $98.4M | ||
| Q3 25 | $289.1M | $46.7M | ||
| Q2 25 | $192.4M | $53.9M | ||
| Q1 25 | $256.6M | $42.2M | ||
| Q4 24 | $419.1M | $94.6M | ||
| Q3 24 | $143.4M | $94.4M | ||
| Q2 24 | $177.5M | $55.4M | ||
| Q1 24 | $295.8M | $26.0M |
毛利率EQRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率EQRRVTY
| Q4 25 | 50.6% | 14.5% | ||
| Q3 25 | 38.5% | 11.7% | ||
| Q2 25 | 26.6% | 12.6% | ||
| Q1 25 | 35.7% | 10.9% | ||
| Q4 24 | 57.2% | 16.3% | ||
| Q3 24 | 20.1% | 14.3% | ||
| Q2 24 | 25.3% | 12.4% | ||
| Q1 24 | 42.0% | 6.8% |
净利率EQRRVTY
| Q4 25 | 48.9% | 12.7% | ||
| Q3 25 | 36.9% | 6.7% | ||
| Q2 25 | 25.0% | 7.5% | ||
| Q1 25 | 33.7% | 6.4% | ||
| Q4 24 | 54.7% | 13.0% | ||
| Q3 24 | 19.2% | 13.8% | ||
| Q2 24 | 24.2% | 8.0% | ||
| Q1 24 | 40.5% | 4.0% |
每股收益（稀释后）EQRRVTY
| Q4 25 | $1.01 | $0.86 | ||
| Q3 25 | $0.76 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $0.67 | $0.35 | ||
| Q4 24 | $1.10 | $0.77 | ||
| Q3 24 | $0.38 | $0.77 | ||
| Q2 24 | $0.47 | $0.45 | ||
| Q1 24 | $0.77 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.9M | $919.9M |
| 总债务越低越好 | $8.2B | — |
| 股东权益账面价值 | $11.0B | $7.3B |
| 总资产 | $20.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.75× | — |
8季度趋势，按日历期对齐
现金及短期投资EQRRVTY
| Q4 25 | $55.9M | $919.9M | ||
| Q3 25 | $93.1M | $931.4M | ||
| Q2 25 | $31.3M | $991.8M | ||
| Q1 25 | $39.8M | $1.1B | ||
| Q4 24 | $62.3M | $1.2B | ||
| Q3 24 | $28.6M | $1.2B | ||
| Q2 24 | $38.3M | $2.0B | ||
| Q1 24 | $44.5M | $1.7B |
总债务EQRRVTY
| Q4 25 | $8.2B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EQRRVTY
| Q4 25 | $11.0B | $7.3B | ||
| Q3 25 | $11.1B | $7.4B | ||
| Q2 25 | $11.0B | $7.6B | ||
| Q1 25 | $11.0B | $7.6B | ||
| Q4 24 | $11.0B | $7.7B | ||
| Q3 24 | $10.9B | $7.9B | ||
| Q2 24 | $11.0B | $7.9B | ||
| Q1 24 | $11.1B | $7.8B |
总资产EQRRVTY
| Q4 25 | $20.7B | $12.2B | ||
| Q3 25 | $21.1B | $12.1B | ||
| Q2 25 | $21.0B | $12.4B | ||
| Q1 25 | $20.6B | $12.4B | ||
| Q4 24 | $20.8B | $12.4B | ||
| Q3 24 | $20.9B | $12.8B | ||
| Q2 24 | $19.8B | $13.4B | ||
| Q1 24 | $19.9B | $13.4B |
负债/权益比EQRRVTY
| Q4 25 | 0.75× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $387.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.01× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EQRRVTY
| Q4 25 | $387.0M | $182.0M | ||
| Q3 25 | $476.7M | $138.5M | ||
| Q2 25 | $359.5M | $134.3M | ||
| Q1 25 | $425.5M | $128.2M | ||
| Q4 24 | $354.2M | $174.2M | ||
| Q3 24 | $401.4M | $147.9M | ||
| Q2 24 | $396.9M | $158.6M | ||
| Q1 24 | $421.0M | $147.6M |
自由现金流EQRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率EQRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度EQRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率EQRRVTY
| Q4 25 | 1.01× | 1.85× | ||
| Q3 25 | 1.65× | 2.97× | ||
| Q2 25 | 1.87× | 2.49× | ||
| Q1 25 | 1.66× | 3.03× | ||
| Q4 24 | 0.85× | 1.84× | ||
| Q3 24 | 2.80× | 1.57× | ||
| Q2 24 | 2.24× | 2.87× | ||
| Q1 24 | 1.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EQR
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
